Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1 7Phase 3 6Phase NA 5Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 6Leukemia 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 4Recurrence 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Follicular 2Leukemia, T-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Congenital Abnormalities 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma, Ewing 1Retinoblastoma 1Primary Myelofibrosis 1Polycythemia Vera 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Thalidomide 4Cyclophosphamide 4carfilzomib 2Melphalan 2Calcium Dobesilate 2trametinib 1tanespimycin 1pomalidomide 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Mesna 1MAGEA3 protein, human 1Lenograstim 1Human Growth Hormone 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Busulfan 1Bone Marrow Transplantation 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Multiple Myeloma × Etoposide × Clear all
NCT03385096 2020-02-25

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
122 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡